Jeffrey Kordower to Neurturin
This is a "connection" page, showing publications Jeffrey Kordower has written about Neurturin.
Connection Strength
4.658
-
GDNF signaling in subjects with minimal motor deficits and Parkinson's disease. Neurobiol Dis. 2021 06; 153:105298.
Score: 0.781
-
Long-term post-mortem studies following neurturin gene therapy in patients with advanced Parkinson's disease. Brain. 2020 03 01; 143(3):960-975.
Score: 0.728
-
AAV2-Neurturin for Parkinson's Disease: What Lessons Have We Learned? Methods Mol Biol. 2016; 1382:485-90.
Score: 0.545
-
Bioactivity of AAV2-neurturin gene therapy (CERE-120): differences between Parkinson's disease and nonhuman primate brains. Mov Disord. 2011 Jan; 26(1):27-36.
Score: 0.382
-
Intrastriatal CERE-120 (AAV-Neurturin) protects striatal and cortical neurons and delays motor deficits in a transgenic mouse model of Huntington's disease. Neurobiol Dis. 2009 Apr; 34(1):40-50.
Score: 0.335
-
Striatal delivery of CERE-120, an AAV2 vector encoding human neurturin, enhances activity of the dopaminergic nigrostriatal system in aged monkeys. Mov Disord. 2007 Jun 15; 22(8):1124-32.
Score: 0.302
-
Neurturin gene therapy improves motor function and prevents death of striatal neurons in a 3-nitropropionic acid rat model of Huntington's disease. Neurobiol Dis. 2007 May; 26(2):375-84.
Score: 0.294
-
Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys. Ann Neurol. 2006 Dec; 60(6):706-15.
Score: 0.291
-
Post-Mortem Studies of Neurturin Gene Therapy for Parkinson's Disease: Two Subjects with 10?Years CERE120 Delivery. Mov Disord. 2023 09; 38(9):1728-1736.
Score: 0.231
-
Gene delivery of neurturin to putamen and substantia nigra in Parkinson disease: A double-blind, randomized, controlled trial. Ann Neurol. 2015 Aug; 78(2):248-57.
Score: 0.131
-
Post-mortem assessment of the short and long-term effects of the trophic factor neurturin in patients with a-synucleinopathies. Neurobiol Dis. 2015 Jun; 78:162-71.
Score: 0.129
-
Properly scaled and targeted AAV2-NRTN (neurturin) to the substantia nigra is safe, effective and causes no weight loss: support for nigral targeting in Parkinson's disease. Neurobiol Dis. 2011 Oct; 44(1):38-52.
Score: 0.100
-
Gene delivery of AAV2-neurturin for Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol. 2010 Dec; 9(12):1164-1172.
Score: 0.095
-
Expression, bioactivity, and safety 1 year after adeno-associated viral vector type 2-mediated delivery of neurturin to the monkey nigrostriatal system support cere-120 for Parkinson's disease. Neurosurgery. 2009 Apr; 64(4):602-12; discussion 612-3.
Score: 0.085
-
Transgene expression, bioactivity, and safety of CERE-120 (AAV2-neurturin) following delivery to the monkey striatum. Mol Ther. 2008 Oct; 16(10):1737-44.
Score: 0.082
-
AAV2-mediated delivery of human neurturin to the rat nigrostriatal system: long-term efficacy and tolerability of CERE-120 for Parkinson's disease. Neurobiol Dis. 2007 Jul; 27(1):67-76.
Score: 0.075
-
Issues regarding gene therapy products for Parkinson's disease: the development of CERE-120 (AAV-NTN) as one reference point. Parkinsonism Relat Disord. 2007; 13 Suppl 3:S469-77.
Score: 0.073